Mark J. Ratain to Antibiotics, Antineoplastic
This is a "connection" page, showing publications Mark J. Ratain has written about Antibiotics, Antineoplastic.
Connection Strength
0.824
-
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res. 2012 Sep 01; 18(17):4785-93.
Score: 0.414
-
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations. Cancer Chemother Pharmacol. 2000; 45(6):489-94.
Score: 0.173
-
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
Score: 0.146
-
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007 Feb 15; 13(4):1246-52.
Score: 0.071
-
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
Score: 0.020